Get the Stockscreener App
0.6151
9.46%
-0.0643
Pre-market:
.62
0.0049
+0.80%
Neumora Therapeutics Inc stock is traded at $0.6151, with a volume of 993.01K.
It is down -9.46% in the last 24 hours and down -8.17% over the past month.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
See More
Previous Close:
$0.6794
Open:
$0.69
24h Volume:
993.01K
Relative Volume:
0.84
Market Cap:
$105.49M
Revenue:
-
Net Income/Loss:
$-274.18M
P/E Ratio:
-0.2427
EPS:
-2.5346
Net Cash Flow:
$-198.33M
1W Performance:
-5.69%
1M Performance:
-8.17%
6M Performance:
-94.74%
1Y Performance:
-93.58%
1-Day Range:
$0.611
$0.7007
1-Week Range:
$0.611
$0.7697
52-Week Range:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Name
Neumora Therapeutics Inc
Sector
Industry
Phone
(857) 760-0900
Address
490 ARSENAL WAY, SUITE 200, WATERTOWN
Compare NMRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
0.6151 | 105.49M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.16 | 111.66B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.36 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
532.27 | 38.04B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.55 | 36.06B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
219.95 | 25.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Downgrade | BofA Securities | Buy → Underperform |
| Mar-10-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-07-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-25 | Downgrade | Stifel | Buy → Hold |
| Jan-02-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-05-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-01-24 | Initiated | H.C. Wainwright | Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Jul-08-24 | Initiated | Mizuho | Outperform |
| Dec-12-23 | Initiated | Deutsche Bank | Hold |
| Oct-10-23 | Initiated | BofA Securities | Buy |
| Oct-10-23 | Initiated | Guggenheim | Buy |
| Oct-10-23 | Initiated | JP Morgan | Overweight |
| Oct-10-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-10-23 | Initiated | Stifel | Buy |
| Oct-10-23 | Initiated | William Blair | Outperform |
View All
Neumora Therapeutics Inc Stock (NMRA) Latest News
Neumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm - PR Newswire
Neumora Therapeutics Venture Debt Facility - Leerink Partners
Neumora Therapeutics Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: Neumora Therapeutics Q1 2025 Sees Net Loss, Stock Rises - Investing.com
Neumora Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Will Neumora Therapeutics (NASDAQ:NMRA) Spend Its Cash Wisely? - Yahoo Finance
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Neumora Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2025NMRA - ACCESS Newswire
Neumora Therapeutics (NMRA) Expected to Announce Earnings on Monday - Defense World
Neumora Therapeutics Inc (NASDAQ: NMRA): What Matters Now - Stocksregister
Schonfeld Strategic Advisors LLC Buys 381,676 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Rating of “Hold” by Analysts - Defense World
Investigation announced for Long-Term Investors in shares - openPR.com
Neumora Therapeutics (NMRA) Projected to Post Quarterly Earnings on Monday - MarketBeat
Invesco Ltd. Raises Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
NMRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - NatLawReview.com
Nothing is Better Than Neumora Therapeutics Inc (NMRA) stock at the moment - Sete News
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Stock Position Increased by Wells Fargo & Company MN - Defense World
Should investors be concerned about Neumora Therapeutics Inc (NMRA)? - uspostnews.com
NMRA stock rated an Underperform by BofA Securities - knoxdaily.com
Wainwright maintains $18 target on Neumora Therapeutics stock By Investing.com - Investing.com Canada
Neumora Therapeutics (NASDAQ:NMRA) versus Big Cypress Acquisition (OTCMKTS:BCYP) Head to Head Comparison - Defense World
Press Release Distribution & PR Platform - ACCESS Newswire
Legal & General Group Plc Buys 50,289 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - The AM Reporter
Neumora Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025 - Yahoo Finance
Investors Who Lost Money on Neumora Therapeutics, Inc. (NMRA) Should Contact Levi & Korsinsky About Pending Class ActionNMRA - ACCESS Newswire
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by Capital International Investors - MarketBeat
It is Poised to be a Bull Market for Neumora Therapeutics Inc (NMRA) - Sete News
NMRA Stock Sees Surge of Approximately 8.37% in Last Five Days - knoxdaily.com
NMRA’s valuation metrics: A comprehensive analysis - uspostnews.com
Former Neumora CEO to lead Galapagos spinout - BioPharma Dive
Franklin Resources Inc. Sells 44,345 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $9.29 Consensus PT from Analysts - MarketBeat
Alliancebernstein L.P. Sells 22,930 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Receives Buy Rating from Needham & Company LLC - MarketBeat
Vanguard Group Inc. Purchases 195,142 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of “Hold” by Analysts - Defense World
Needham & Company LLC Reaffirms “Buy” Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World
KLP Kapitalforvaltning AS Makes New Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc.: Strategic Advancements and Optimism Drive Buy Rating - TipRanks
Levi & Korsinsky Notifies Shareholders of Neumora Therapeutics, Inc.(NMRA) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
NMRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Neumora Therapeutics Inc Stock (NMRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):